We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Availability of Diphtheria Antitoxin Through an Investigational New Drug Protocol.
- Abstract
Focuses on the availability of diphtheria antitoxin in the United States. Cause of respiratory diphtheria; Treatment with equine diphtheria antitoxin (DAT); Complications from the disease if left untreated; Expiration date of the DAT product made by France's Pasteur Merieux and approved under a U.S. Food and Drug Administration program, Investigational New Drug protocol; Indication that a supply of DAT was purchased by the CDC from the Instituto Butantan in Brazil; How physicians can obtain DAT from the CDC Bacterial Vaccine Preventable Disease Branch in the Epidemiology and Surveillance Division of the National Immunization Program.
- Subjects
UNITED States; FRANCE; BRAZIL; DIPHTHERIA antitoxin; PUBLIC health; DIPHTHERIA treatment; PASTEUR Merieux Connaught Laboratories Ltd.; UNITED States. Food &; Drug Administration; CENTERS for Disease Control &; Prevention (U.S.)
- Publication
JAMA: Journal of the American Medical Association, 2004, Vol 292, Issue 2, p166
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.292.2.166